These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27033163)

  • 1. Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.
    Haladyna JN; Pastuer T; Riedel SS; Perraud AL; Bernt KM
    Exp Hematol; 2016 Jul; 44(7):596-602.e3. PubMed ID: 27033163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.
    Liu Q; Chen L; Atkinson JM; Claxton DF; Wang HG
    Cell Death Dis; 2016 Sep; 7(9):e2361. PubMed ID: 27607576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
    Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
    Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heritable genetic background alters survival and phenotype of Mll-AF9-induced leukemias.
    Young K; Loberg MA; Eudy E; Schwartz LS; Mujica KD; Trowbridge JJ
    Exp Hematol; 2020 Sep; 89():61-67.e3. PubMed ID: 32768438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
    Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.
    Chen L; Chen W; Mysliwski M; Serio J; Ropa J; Abulwerdi FA; Chan RJ; Patel JP; Tallman MS; Paietta E; Melnick A; Levine RL; Abdel-Wahab O; Nikolovska-Coleska Z; Muntean AG
    Leukemia; 2015 Jun; 29(6):1290-300. PubMed ID: 25650089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of the Shb gene in mixed-lineage leukemia MLL-AF9 cells increases latency in mice despite higher proliferation rates in vitro.
    Jamalpour M; Bergquist E; Welsh M
    Exp Cell Res; 2020 Dec; 397(2):112368. PubMed ID: 33220260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.
    Zhang J; Seet CS; Sun C; Li J; You D; Volk A; Breslin P; Li X; Wei W; Qian Z; Zeleznik-Le NJ; Zhang Z; Zhang J
    Mol Oncol; 2013 Dec; 7(6):1069-82. PubMed ID: 23988911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
    Chen L; Sun Y; Wang J; Jiang H; Muntean AG
    Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
    Chu Y; Chen Y; Guo H; Li M; Wang B; Shi D; Cheng X; Guan J; Wang X; Xue C; Cheng T; Shi J; Yuan W
    Oncogene; 2020 Dec; 39(50):7239-7252. PubMed ID: 33037410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cells.
    Gil-Kulik P; Dudzińska E; Radzikowska-Büchner E; Wawer J; Jojczuk M; Nogalski A; Wawer GA; Feldo M; Kocki W; Cioch M; Bogucka-Kocka A; Rahnama M; Kocki J
    BMC Cancer; 2020 May; 20(1):435. PubMed ID: 32423430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model.
    Bergerson RJ; Collier LS; Sarver AL; Been RA; Lugthart S; Diers MD; Zuber J; Rappaport AR; Nixon MJ; Silverstein KA; Fan D; Lamblin AF; Wolff L; Kersey JH; Delwel R; Lowe SW; O'Sullivan MG; Kogan SC; Adams DJ; Largaespada DA
    Blood; 2012 May; 119(19):4512-23. PubMed ID: 22427200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
    Sontakke P; Carretta M; Jaques J; Brouwers-Vos AZ; Lubbers-Aalders L; Yuan H; de Bruijn JD; Martens AC; Vellenga E; Groen RW; Schuringa JJ
    Leukemia; 2016 Oct; 30(10):2064-2073. PubMed ID: 27125308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis.
    Bagislar S; Sabò A; Kress TR; Doni M; Nicoli P; Campaner S; Amati B
    Oncotarget; 2016 Oct; 7(41):66398-66415. PubMed ID: 27655694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia.
    Kamezaki K; Luchsinger LL; Snoeck HW
    Exp Hematol; 2014 Mar; 42(3):192-203.e1. PubMed ID: 24269847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
    Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
    Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?
    Muntean AG; Hess JL
    Cancer Cell; 2008 Jun; 13(6):465-7. PubMed ID: 18538728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Acetyltransferase Activity of MOF Is Required for
    Valerio DG; Xu H; Chen CW; Hoshii T; Eisold ME; Delaney C; Cusan M; Deshpande AJ; Huang CH; Lujambio A; Zheng YG; Zuber J; Pandita TK; Lowe SW; Armstrong SA
    Cancer Res; 2017 Apr; 77(7):1753-1762. PubMed ID: 28202522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
    Jin Y; Lu Z; Ding K; Li J; Du X; Chen C; Sun X; Wu Y; Zhou J; Pan J
    Cancer Res; 2010 Mar; 70(6):2516-27. PubMed ID: 20215516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.